The Recall Desk
HighFDA (Drugs)·D-0356-2026·Announced 2026-03-11

Teva metoprolol succinate 100 mg tablets failed dissolution specifications

Teva Pharmaceuticals is recalling six lots of Metoprolol Succinate Extended-Release Tablets 100 mg after the product failed dissolution specifications.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported: an extended-release cardiovascular medicine may not release its dose as specified, and no injuries are stated in the source.

Plain-English summary

Teva Pharmaceuticals USA, Inc is recalling Metoprolol Succinate Extended-Release Tablets, 100 mg, prescription only, in 100-tablet bottles (NDC 45963-677-11) and 1,000-tablet bottles (NDC 45963-677-96). About 7,448 bottles were distributed nationwide. The FDA has classified this recall as Class II.

The recall was initiated because the product failed dissolution specifications.

Affected product covers lots 0718J251, 0729J251, 0730J251, 0718J252, 0729J252 and 0730J252, all with an expiry date of 12/2026.

Patients and pharmacies can identify affected product by the NDC and lot numbers above, and may contact Teva Pharmaceuticals USA, Inc for further information.

The recalled product

Product
METOPROLOL SUCCINATE (METOPROLOL SUCCINATE)
Brand
METOPROLOL SUCCINATE
Manufacturer
Teva Pharmaceuticals USA, Inc
Hazard
  • failed-dissolution
  • extended-release
  • dosing-risk

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (8)

  • Lot#: a) 0718J251
  • 0729J251
  • 0730J251
  • Exp.: 12/2026
  • b) 0718J252
  • 0729J252
  • 0730J252
  • Exp.: 12/2026.

Distribution

Distributed nationwide across the United States.